BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin's lymphoma.

Simian virus 40 (SV40) is associated with some systemic non-Hodgkin's lymphomas (NHL) among HIV-positive patients, based on assays for viral DNA sequences.

To investigate the possible production of the viral transforming protein, we examined age-matched case-control specimens from patients with HIV/AIDS for the expression of SV40 large tumor antigen (T-ag).

Fifty-five systemic NHL and 25 nonmalignant lymphoid and malignant nonlymphoid tissue control cases from two HIV community programs in Texas and New Jersey were scored for IHC positivity without knowledge of the PCR results.

SV40 T-ag expression was detected only in B-cell lymphoma specimens that contained SV40 DNA sequences.

Not all lymphoma cells in a positive specimen stained for T-ag, and the reaction was lower intensity than observed in SV40 hamster tumors.

A germinal center B-cell-like (GCB) profile was more frequently expressed by SV40-positive tumors than in Epstein-Barr virus (EBV)-related lymphomas (10/12, 83% vs. 6/13, 46%; P = 0.05), whereas a non-GCB phenotype was more frequent in EBV-positive than in SV40-positive lymphomas (7/13, 54% vs. 2/12, 17%; P = 0.05).

This study shows that SV40 gene expression occurs in a fraction of cells in some B-cell lymphomas among patients with HIV/AIDS.

[MeSH-major] Antigens, Polyomavirus Transforming / genetics. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / virology

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16122775.001).

[ISSN] 0042-6822

[Journal-full-title] Virology

[ISO-abbreviation] Virology

[Language] eng

[Grant] United States / NIAID NIH HHS / AI / AI36211; United States / NCI NIH HHS / CA / CA104818

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / DNA, Viral

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immune reconstitution inflammatory syndrome in AIDS-related non-hodgkin's lymphoma.

Immune Reconstitution syndrome following antiretroviral therapy is common in HIV/AIDS patients due to boosting of immunity.

A case is reported here wherein AIDS-related Non-Hodgkin's lymphoma patient received CHOP regimen and antiretroviral therapy.

HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20838562.001).

[ISSN] 0975-2129

[Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology

[ISO-abbreviation] Indian J Med Paediatr Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Other-IDs] NLM/ PMC2930308

[Keywords] NOTNLM ; AIDS-related lymphoma / HIV-IRIS / IRIS

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary pulmonary AIDS-related lymphoma.

Extranodal involvement is common in lymphomas associated with human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS).

However, primary pulmonary AIDS-related non-Hodgkin's lymphoma is very rare and only few reports were published in the medical literature.

Primary pulmonary lymphoma associated with AIDS is generally a high-grade B-cell non-Hodgkin lymphoma and Epstein-Barr virus is strongly associated with the pathogenesis of these tumors.

We report a patient with AIDS and primary pulmonary lymphoma which clinical presentation was a total atelectasis of the left lung.

[MeSH-major] Lung Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Pulmonary Atelectasis / etiology

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Collapsed Lung.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16138208.001).

[ISSN] 0036-4665

[Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo

[ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Brazil

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma.

CXCL13/CXCR5 are expressed, and may play a role, in some non-AIDS-associated B cell tumors.

Objective. To determine if CXCL13/CXCR5 are associated with AIDS-related non-Hodgkin's lymphoma (AIDS-NHL).

Methods. Serum CXCL13 levels were measured by ELISA in 46 subjects who developed AIDS-NHL in the Multicenter AIDS Cohort Study and in controls.

The expression or function of CXCL13 and CXCR5 was examined on primary AIDS-NHL specimens or AIDS-NHL cell lines.

Results. Serum CXCL13 levels were significantly elevated in the AIDS-NHL group compared to controls.

All primary AIDS-NHL specimens showed CXCR5 expression and most also showed CXCL13 expression.

AIDS-NHL cell lines expressed CXCR5 and showed chemotaxis towards CXCL13.

Conclusions. CXCL13/CXCR5 are expressed in AIDS-NHL and could potentially be involved in its biology.

CXCL13 may have potential as a biomarker for AIDS-NHL.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Pathol. 2008 Aug;215(4):431-44 [18561120.001]

[Cites] J Neuroimmunol. 2008 Jul 31;198(1-2):106-12 [18539341.001]

[Cites] Blood. 2009 May 7;113(19):4604-13 [19228923.001]

[Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]

[Cites] J Clin Oncol. 1993 Jun;11(6):1099-107 [8099121.001]

[Cites] Blood. 1994 Feb 15;83(4):1067-78 [8111047.001]

[Cites] Cell. 1996 Dec 13;87(6):1037-47 [8978608.001]

[Cites] Blood. 1997 Jul 15;90(2):520-5 [9226150.001]

[Cites] J Exp Med. 1998 Feb 16;187(4):655-60 [9463416.001]

[Cites] Nature. 1998 Feb 19;391(6669):799-803 [9486651.001]

[Cites] Oncology (Williston Park). 2001 Apr;15(4):439-48; discussion 448-9 [11346932.001]

[Cites] Curr Opin Oncol. 2002 Sep;14(5):528-32 [12192272.001]

[Cites] Ophthalmology. 2003 Feb;110(2):421-6 [12578791.001]

[Cites] Tumour Biol. 2003 Mar-Apr;24(2):82-93 [12853703.001]

[Cites] Breast Dis. 2004;20:137-43 [15687714.001]

[Cites] J Natl Cancer Inst. 1991 May 15;83(10):695-701 [2023270.001]

[Cites] Blood. 1995 Jun 15;85(12):3423-30 [7780129.001]

[Cites] Biochem Biophys Res Commun. 1997 Jun 27;235(3):576-81 [9207199.001]

[Cites] Blood. 1999 Mar 15;93(6):1838-42 [10068655.001]

[Cites] Blood Rev. 1999 Sep;13(3):147-50 [10527266.001]

[Cites] Immunology. 2000 Feb;99(2):266-71 [10692046.001]

[Cites] Immunity. 2000 Feb;12(2):121-7 [10714678.001]

[Cites] Immunol Rev. 2000 Aug;176:181-93 [11043777.001]

[Cites] Biochem Biophys Res Commun. 2001 Mar 30;282(2):369-75 [11401467.001]

[Cites] Eur J Cancer. 2001 Jul;37(10):1270-5 [11423258.001]

[Cites] Cancer Res. 2001 Jul 1;61(13):5028-37 [11431337.001]

[Cites] Blood. 2002 Jan 1;99(1):207-12 [11756173.001]

[Cites] Nature. 2002 Mar 7;416(6876):94-9 [11882900.001]

[Cites] Cancer Res. 2002 Jun 1;62(11):3106-12 [12036921.001]

[Cites] J Leukoc Biol. 2002 Jul;72(1):1-8 [12101256.001]

[Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]

[Cites] J Virol. 2003 Feb;77(3):2271-5 [12525664.001]

[Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86 [12626353.001]

[Cites] Blood. 2004 Jul 15;104(2):502-8 [15001469.001]

[Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]

[Cites] Int J Dev Biol. 2004;48(5-6):489-96 [15349823.001]

[Cites] AIDS. 2005 Oct 14;19(15):1711-2 [16184051.001]

[Cites] J Interferon Cytokine Res. 2005 Nov;25(11):702-6 [16318584.001]

[Cites] Acta Neuropathol. 2007 Sep;114(3):271-6 [17641901.001]

[Cites] Blood. 2007 Nov 1;110(9):3316-25 [17652619.001]

[Cites] Immunity. 2007 Aug;27(2):190-202 [17723214.001]

[Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]

[Cites] Blood. 2008 Mar 15;111(6):3200-10 [18184868.001]

[Cites] Blood. 2008 Dec 1;112(12):4401-10 [18780835.001]

(PMID = 21490903.001).

[ISSN] 2090-1259

[Journal-full-title] AIDS research and treatment

[ISO-abbreviation] AIDS Res Treat

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCI NIH HHS / CA / R01 CA073475; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NCI NIH HHS / CA / R01 CA057152; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI035039

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC3065842

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy.

Since HAART became available in 1996, the incidence of AIDS-related non-Hodgkin's lymphoma (NHL) has fallen, and although there has been no change in the clinical features at presentation, the overall survival of patients with AIDS-related NHL has improved.

Prognosis is now determined chiefly by lymphoma-associated factors similar to those in the general population (the International Prognostic Index), although serum CD4 count at lymphoma diagnosis is an additional independent prognostic factor.

The management of patients with AIDS-related NHL with either infusional chemotherapy or CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine and prednisolone) achieves response and survival rates approaching those observed in the general population.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Neutropenia / therapy. Sarcoma, Kaposi / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17085516.001).

[ISSN] 1460-2725

[Journal-full-title] QJM : monthly journal of the Association of Physicians

[ISO-abbreviation] QJM

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 91

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lymphoproliferative clonal origin of AIDS-related non-Hodgkin's lymphoma.

[MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / genetics. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / genetics. Lymphoproliferative Disorders / genetics

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17454643.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma.

OBJECTIVES: To develop effective non-myelotoxic therapies for Burkitt's Lymphoma (BL) and AIDS-related non-Hodgkin's lymphoma.

CONCLUSION: Myelotoxic death rates using multi-agent induction chemotherapy approach 25% for endemic Burkitt's lymphoma and range between 20% to 60% for AIDS-related malignancy.

Investigations and alternative approaches that lessen or circumvent myelotoxicity of traditional cytotoxic chemotherapy for the management of Burkitt's lymphoma and AIDS-related non-Hodgkin's lymphoma in the resource-constrained setting are warranted.

This can be achieved by developing targeted anti-viral and other strategies, such as the use of bryostatin 1 and vincristine, and by developing a preclinical mouse model to frame the clinical rationale for a pilot trial of metronomic therapy for the treatment of Burkitt's and AIDS-related lymphoma.

[MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy. Macrolides / therapeutic use. Vincristine / therapeutic use

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16619692.001).

[ISSN] 0012-835X

[Journal-full-title] East African medical journal

[ISO-abbreviation] East Afr Med J

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Kenya

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine

[Number-of-references] 38

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy.

BACKGROUND AND OBJECTIVES: Lymphoma is the fourth most frequent malignancy diagnosed during pregnancy, occurring in approximately 1 over 6000 deliveries.

DESIGN AND METHODS: Its occurrence may increase due to the current trend to postpone pregnancy until later in life and the evidence suggested high incidence of AIDS-related non-Hodgkin's lymphoma in developing countries.

The relatively rare occurrence of pregnancy-associated lymphoma precludes the conduction of large, prospective studies to examine diagnostic, management and outcome issues.

In the vast majority of cases, when lymphoma is diagnosed during the first trimester, treatment with a standard chemotherapy regimen, following pregnancy termination should be recommended.

In the rare patients at low risk, such as those with stage 1 Hodgkin's lymphoma or indolent non-Hodgkins lymphoma, therapy can be delayed until the end of the first trimester and of embryogenesis while keeping the patients under close observation.

INTERPRETATION AND CONCLUSIONS: When lymphoma is diagnosed during the second and third trimesters, evidence exists suggesting that full-dose chemotherapy can be administered safely without apparent increased risk of severe adverse fetal outcome.

[MeSH-major] Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Pregnancy Complications, Neoplastic / therapy

Genetic Alliance. consumer health - Pregnancy.

MedlinePlus Health Information. consumer health - Hodgkin Disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17666365.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Italy

[Number-of-references] 67

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphoma.

[MeSH-major] Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] J Clin Oncol. 2005 Jul 1;23(19):4430-8 [15883411.001]

(PMID = 16293885.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comment; Letter

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.

BACKGROUND: The majority of patients with AIDS-related non-Hodgkin's lymphoma (ARL) present with advanced disease, aggressive histological type, B-symptoms, and often with an extranodal localization.

Twenty-six patients had an aggressive type of lymphoma while 2 had an indolent type.

RESULTS: This study demonstrated that significant factors for OS in patients with ARL were the high International Prognostic Index (P=0.019), previous AIDS event (P=0.04), aggressive histological type of NHL (P=0.007) and extranodal disease (P=0.04).

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

Hazardous Substances Data Bank. BLEOMYCIN .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17629445.001).

[ISSN] 0753-3322

[Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie

[ISO-abbreviation] Biomed. Pharmacother.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] France

[Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of non-Hodgkin's lymphoma.

Immunocompromised patients are at risk of developing Epstein-Barr virus (EBV)-related lymphoproliferative disorders.

Quantitative determination of serum EBV DNA permits early diagnosis of an AIDS-related non-Hodgkin's lymphoma, and surveillance of treatment response and/or relapse, and thus may be a useful tool to monitor disease activity.

[MeSH-major] DNA, Viral / blood. HIV Infections / virology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15965829.001).

[ISSN] 1424-7860

[Journal-full-title] Swiss medical weekly

[ISO-abbreviation] Swiss Med Wkly

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Anti-HIV Agents; 0 / DNA, Viral; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma.

METHODS: The study included 91 patients with AIDS-related non-Hodgkin's lymphoma from the Swiss HIV Cohort Study enrolled between January 1997 and October 2003, excluding lymphomas of the brain.

We extracted AIDS-related non-Hodgkin's lymphoma- and HIV-specific variables at the time of lymphoma diagnosis as well as treatment changes over time from charts and from the Swiss HIV Cohort Study database.

The effect of cART interruptions on AIDS-related non-Hodgkin's lymphoma prognosis remains unclear, however, hepatitis C seropositivity emerged-as a predictor of death beyond the well-known international prognostic index score and CD4+ T-cell count.

[MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17926647.001).

[ISSN] 1359-6535

[Journal-full-title] Antiviral therapy

[ISO-abbreviation] Antivir. Ther. (Lond.)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Treatment of non-Hodgkin's lymphoma associated with acquired immnodeficiency syndrome (AIDS) at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán].

[Transliterated title] Tratamiento de pacientes con linfomas no Hodgkin asociados a SIDA: experiencia del Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.

BACKGROUND: Survival in patients with acquired immunodeficiency syndrome (AIDS) related non-Hodgkin's Lymphoma has improved with the use of High Active Antiretroviral Therapy (HAART) and less toxic chemotherapy.

MATERIAL AND METHODS: Clinical characteristics and outcome among patients treated for AIDS related non-Hodgkin's Lymphoma are described.

[MeSH-major] Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16711542.001).

[ISSN] 0016-3813

[Journal-full-title] Gaceta médica de México

[ISO-abbreviation] Gac Med Mex

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Mexico

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).

Non-Hodgkin's lymphoma is an AIDS-defining disease.

We collected data of 214 cases of AIDS-related Lymphoma (ARL) treated at our centre from January 1984 until May 2003 and analysed them using the Kaplan-Meier-, log rank- and Cox proportional hazard-model.

The incidence of AIDS-related primary CNS lymphomas (PCNSL) took a comparable, yet more pronounced development.

No significant differences could be shown for the use of protease inhibitors as well as for virological response being achieved before the diagnosis of NHL.

Classical prognostic factors (CD4 count, prior Kaposi Sarcoma, extranodal manifestation, staging and histological subtype of NHL) were no longer significant for HAART patients in the multivariate analysis.

[MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15621803.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antiviral Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy.

Using the population-based cancer registry, we identified 233 patients with AIDS-related systemic NHL diagnosed in San Diego or Orange County in 1994-1999, of whom 137 were diagnosed 1996-1999.

We performed Kaplan-Meier analyses to compare survival between patients who received HAART at NHL diagnosis or thereafter versus untreated patients and Cox proportional hazard models for adjusted survival.

Among patients diagnosed with NHL in 1996-1999, 40 (29%) were taking HAART at NHL diagnosis.

HAART, chemotherapy, high performance status, and NHL stage < IV were associated with improved survival.

Concomitant HAART, completion of > or = 6 chemotherapy cycles, and NHL stage < IV were associated with complete response to chemotherapy.

We conclude that HAART should be initiated or continued after NHL diagnosis, including during the period of chemotherapy administration.

[MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2006 John Wiley & Sons, Ltd.

(PMID = 16604565.001).

[ISSN] 0278-0232

[Journal-full-title] Hematological oncology

[ISO-abbreviation] Hematol Oncol

[Language] eng

[Grant] United States / NCI NIH HHS / CA / K07CA096480

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.

PURPOSE: To evaluate the safety and efficacy of rituximab adjunction to the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma.

PATIENTS AND METHODS: HIV-seropositive patients with high-grade lymphoma of B-cell origin were eligible if they had no more than one of the following characteristics: CD4 cell count less than 100/microL, prior AIDS, or performance status less than 2.

Characteristics of patients were median age, 41 years; median CD4 cells, 172/microL; histology, diffuse large B-cell lymphoma (n = 42), immunoblastic (n = 2), Burkitt lymphoma (n = 16), and plasmablastic (n = 1); 42 patients with stage III to IV; International Prognostic Index 0 to 1 (n=31), and 2 to 3 (n = 27).

Eighteen patients died: 16 as a result of lymphoma, one as a result of infection, and one as a result of encephalitis.

CONCLUSION: Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with AIDS-related non-Hodgkin's lymphoma, without increasing the risk of life-threatening infections.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Hodgkin Disease.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e6 [17308260.001]

[CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e7 [17308261.001]

(PMID = 16896005.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.

PURPOSE Africa is burdened by the AIDS epidemic and attendant increase in HIV/AIDS-related malignancies.

Dose-modified oral chemotherapy for AIDS-related non-Hodgkin's lymphoma is one such approach.

PATIENTS AND METHODS The oral regimen consisted of lomustine 50 mg/m(2) on day 1 (cycle 1 only), etoposide 100 mg/m(2) on days 1 to 3, and cyclophosphamide/procarbazine 50 mg/m(2) each on days 22 to 26 at 6-week intervals (one cycle) for two total cycles in HIV-infected patients with biopsy-proven non-Hodgkin's lymphoma.

Four febrile neutropenia episodes and three treatment-related deaths (6% mortality rate) occurred.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV-1 / physiology. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

Hazardous Substances Data Bank. LOMUSTINE .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]

[Cites] Med Pediatr Oncol. 2003 Dec;41(6):532-40 [14595710.001]

[Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]

[Cites] Am J Med. 1986 Jan;80(1):119-22 [3942143.001]

[Cites] Ann Intern Med. 1989 Jun 1;110(11):937-40 [2719427.001]

[Cites] Rev Infect Dis. 1989 Nov-Dec;11(6):954-63 [2690289.001]

[Cites] J Acquir Immune Defic Syndr. 1990;3(4):430-7 [2313564.001]

[Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]

[Cites] Blood. 1993 May 15;81(10):2810-5 [8490187.001]

[Cites] Drugs. 1999;58 Suppl 3:99-107 [10711848.001]

[Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]

[Cites] Ann N Y Acad Sci. 2000 Nov;918:362-6 [11131726.001]

[Cites] Am J Hematol. 2001 Mar;66(3):178-88 [11279624.001]

[Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]

[Cites] Biometrics. 1999 Jun;55(2):625-9 [11318225.001]

[Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]

[Cites] J Am Coll Nutr. 2001 Dec;20(6):609-15 [11771676.001]

[Cites] J Natl Cancer Inst. 2002 May 15;94(10):718-32 [12011222.001]

[Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]

[Cites] Curr Opin Oncol. 2004 Sep;16(5):468-76 [15314517.001]

[Cites] J Clin Oncol. 1993 Sep;11(9):1691-702 [8355036.001]

[Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]

[Cites] Leuk Lymphoma. 1994 Jul;14(3-4):263-71 [7950915.001]

[Cites] J Clin Oncol. 1996 Nov;14(11):3026-35 [8918501.001]

[Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]

[Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]

[Cites] AIDS. 1998;12 Suppl 1:S3-14 [9677185.001]

[Cites] Haematologica. 1998 Jun;83(6):508-13 [9676023.001]

[Cites] J Clin Oncol. 1998 Nov;16(11):3601-6 [9817281.001]

[Cites] Pediatr Blood Cancer. 2005 Mar;44(3):245-50 [15547922.001]

[Cites] Cancer Detect Prev. 2005;29(2):133-45 [15829373.001]

[Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]

[Cites] East Afr Med J. 2005 Sep;82(9 Suppl):S155-60 [16619692.001]

[Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]

[Cites] Curr Opin Oncol. 2006 Sep;18(5):479-86 [16894296.001]

[Cites] N Engl J Med. 2006 Sep 14;355(11):1141-53 [16971720.001]

[Cites] Lancet Oncol. 2008 Apr;9(4):319 [18380064.001]

[Cites] Nat Rev Cancer. 2008 May;8(5):398-403 [18385682.001]

[Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]

[Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]

[Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]

[Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]

(PMID = 19470940.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Grant] United States / FIC NIH HHS / TW / TW00011; United States / NCI NIH HHS / CA / R01 CA083528; United States / NIAID NIH HHS / AI / AI36219; United States / NCI NIH HHS / CA / CA83528; United States / NCI NIH HHS / CA / U01 CA070081; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA066531; United States / NCI NIH HHS / CA / CA43703; United States / FIC NIH HHS / TW / D43 TW000011; United States / NCI NIH HHS / CA / CA70081; United States / NCI NIH HHS / CA / U01 CA066531; United States / NIAID NIH HHS / AI / P30 AI036219

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide

[Other-IDs] NLM/ PMC2717754

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.

Human immunodeficiency virus (HIV)-infected patients are at increased risk of developing cancer, particularly in the later stages of acquired immune deficiency syndrome (AIDS).

Kaposi's sarcoma (KS) and AIDS-related non-Hodgkin's lymphoma (ARL) are the most common AIDS-defining malignancies.

AIDS-related KS varies from minimal to fulminant disease.

Treatment decisions for AIDS-related KS are guided largely by the presence and extent of symptomatic disease.

Novel therapies that have become available to treat AIDS-related KS include angiogenesis inhibitors and antiviral agents.

HIV-infected patients also appear to be at increased risk for developing certain non-AIDS-defining cancers, such as Hodgkin's lymphoma and multiple myeloma.

Although the optimal treatment of these neoplasms is at present uncertain, recent advances in chemotherapy, antiretroviral drugs, and supportive care protocols are allowing for more aggressive management of many of the AIDS-related cancers.

This article provides an up-to-date review of the epidemiology, pathogenesis, clinical features, and treatment of various AIDS-related malignancies that are likely to be encountered by an oncologist practicing in the current HAART era.

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Medical Oncology / trends. Sarcoma, Kaposi / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

MedlinePlus Health Information. consumer health - Hodgkin Disease.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15967835.001).

[ISSN] 1083-7159

[Journal-full-title] The oncologist

[ISO-abbreviation] Oncologist

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Number-of-references] 157

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma.

Despite highly active antiretroviral therapy (HAART), AIDS related lymphoma (ARL) occurs at a significantly higher rate in patients infected with the Human Immunodeficiency Virus (HIV) than in the general population.

We sequenced HIV-1 envelope gp120 clones obtained post mortem from several tumor and non-tumor tissues of two patients who died with AIDS-related Non-Hodgkin's lymphoma (ARL-NH).

1) high-resolution phylogenetic analysis showed a significant degree of compartmentalization between lymphoma and non-lymphoma viral sub-populations while viral sub-populations from lymph nodes appeared to be intermixed within sequences from tumor and non-tumor tissues, 2) a 100-fold increase in the effective HIV population size in tumor versus non-tumor tissues was associated with the emergence of lymphadenopathy and aggressive metastatic ARL, and 3) HIV gene flow among lymph nodes, normal and metastatic tissues was non-random.

The different population dynamics between the viruses found in tumors versus the non-tumor associated viruses suggest that there is a significant relationship between HIV evolution and lymphoma pathogenesis.

Genetic Alliance. consumer health - HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]

[Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]

[Cites] Genetics. 2006 Apr;172(4):2665-81 [16489234.001]

[Cites] Nat Cell Biol. 2006 Dec;8(12):1369-75 [17128264.001]

[Cites] Clin Lymphoma Myeloma. 2007 Jan;7(4):272-9 [17324334.001]

[Cites] PLoS Comput Biol. 2007 Feb 16;3(2):e29 [17305421.001]

[Cites] PLoS One. 2007;2(9):e950 [17895991.001]

[Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]

[Cites] Leuk Lymphoma. 2007 Dec;48(12):2403-11 [18067016.001]

[Cites] Retrovirology. 2007;4:87 [18053211.001]

[Cites] BMC Evol Biol. 2007;7:214 [17996036.001]

[Cites] Mol Phylogenet Evol. 2008 Nov;49(2):618-28 [18801446.001]

[Cites] Nat Rev Cancer. 2009 Apr;9(4):285-93 [19308068.001]

[Cites] PLoS One. 2009;4(3):e5065 [19333384.001]

[Cites] Genetics. 2000 Jul;155(3):1429-37 [10880500.001]

[Cites] AIDS. 2000 Dec 22;14(18):2937-9 [11153675.001]

[Cites] Mol Biol Evol. 2001 Jun;18(6):1001-13 [11371589.001]

[Cites] Science. 2001 Dec 14;294(5550):2310-4 [11743192.001]

[Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]

[Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]

[Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]

[Cites] Syst Biol. 2003 Oct;52(5):696-704 [14530136.001]

[Cites] Science. 2004 Jan 16;303(5656):327-32 [14726583.001]

[Cites] Bioinformatics. 2004 Feb 12;20(3):436-8 [14960476.001]

[Cites] Genetics. 1989 Nov;123(3):603-13 [2599370.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]

[Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):379-85 [7882103.001]

[Cites] Comput Appl Biosci. 1997 Oct;13(5):555-6 [9367129.001]

[Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]

[Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]

[Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]

[Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]

[Cites] Mol Biol Evol. 2005 May;22(5):1185-92 [15703244.001]

[Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]

[Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]

[Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]

(PMID = 19997510.001).

[ISSN] 1932-6203

[Journal-full-title] PloS one

[ISO-abbreviation] PLoS ONE

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U01 CA096230; United States / NCI NIH HHS / CA / U01 CA096230-06; United States / NIAID NIH HHS / AI / R01 AI065265; United States / NINDS NIH HHS / NS / NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA009126; United States / NINDS NIH HHS / NS / R01 NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529-14; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA09126

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / HIV Core Protein p24; 0 / HIV Envelope Protein gp120

[Other-IDs] NLM/ PMC2780293

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6.

BACKGROUND: AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) is the second most frequent cancer associated with AIDS, and is a frequent cause of death in HIV-infected individuals.

Experimental analysis of AIDS-NHL has been facilitated by the availability of an excellent animal model, i.e., simian Acquired Immunodeficiency Syndrome (SAIDS) in the rhesus macaque consequent to infection with simian immunodeficiency virus.

A recent study of SAIDS-NHL demonstrated a lymphoma-derived cell line to be sensitive to the growth inhibitory effects of the ubiquitous cytokine, transforming growth factor-beta (TGF-beta).

The authors concluded that TGF-beta acts as a negative growth regulator of the lymphoma-derived cell line and, potentially, as an inhibitory factor in the regulatory network of AIDS-related lymphomagenesis.

The present study was conducted to assess whether other SAIDS-NHL and AIDS-NHL cell lines are similarly sensitive to the growth inhibitory effects of TGF-beta, and to test the hypothesis that interleukin-6 (IL-6) may represent a counteracting positive influence in their growth regulation.

Intracellular flow cytometry was used to analyze the activation of signaling pathways and to examine the expression of anti-apoptotic proteins and distinguishing hallmarks of AIDS-NHL subclass.

RESULTS: Results confirmed the sensitivity of LCL8664, an immunoblastic SAIDS-NHL cell line, to TGF-beta1-mediated growth inhibition, and further demonstrated the partial rescue by simultaneous treatment with IL-6.

By comparison, human AIDS-NHL cell lines differed in their responsiveness to TGF-beta1 and IL-6.

Analysis of a recently derived AIDS-NHL cell line, UMCL01-101, indicated that it represents immunoblastic AIDS-DLCBL.

CONCLUSION: These studies indicate that the sensitivity of immunoblastic AIDS- or SAIDS-DLBCL to TGF-beta1-mediated growth inhibition may be overcome through the stimulation of proliferative and anti-apoptotic signals by IL-6, particularly through the rapid activation of STAT3.

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1477-85 [10555111.001]

[Cites] J Biol Chem. 1999 Aug 13;274(33):23013-9 [10438468.001]

[Cites] AIDS Res Hum Retroviruses. 2000 Jan 20;16(2):163-71 [10659055.001]

[Cites] Oncogene. 2000 May 15;19(21):2468-73 [10851045.001]

[Cites] Oncogene. 2000 May 15;19(21):2496-504 [10851048.001]

[Cites] Oncogene. 2000 May 15;19(21):2548-56 [10851053.001]

[Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]

[Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]

[Cites] J Immunol. 2000 Sep 1;165(5):2500-10 [10946276.001]

[Cites] Leuk Lymphoma. 2000 Aug;38(5-6):481-8 [10953968.001]

[Cites] Blood. 2000 Dec 15;96(13):4084-90 [11110677.001]

[Cites] FEBS Lett. 2001 Jan 19;488(3):179-84 [11163768.001]

[Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]

[Cites] Clin Cancer Res. 2001 Mar;7(3):709-23 [11297268.001]

[Cites] Oncogene. 2001 Feb 8;20(6):677-85 [11314001.001]

[Cites] Oncogene. 2001 May 3;20(20):2499-513 [11420660.001]

[Cites] AIDS Res Hum Retroviruses. 2001 May 20;17(8):745-51 [11429114.001]

[Cites] J Med Virol. 2001 Sep;65(1):114-20 [11505452.001]

[Cites] Oncogene. 2001 Sep 13;20(41):5799-809 [11593385.001]

[Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]

[Cites] Blood. 2002 Jul 1;100(1):194-9 [12070027.001]

[Cites] Clin Cancer Res. 2003 Jan;9(1):316-26 [12538484.001]

[Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3867-72 [12553006.001]

[Cites] Int J Cancer. 2003 Jul 10;105(5):661-8 [12740915.001]

[Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]

[Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]

[Cites] Leukemia. 2003 Sep;17(9):1731-7 [12970772.001]

[Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]

[Cites] Rev Physiol Biochem Pharmacol. 2003;149:1-38 [12687404.001]

[Cites] J Virol. 2004 Feb;78(4):1697-705 [14747535.001]

[Cites] Vet Pathol. 1988 Nov;25(6):456-67 [2850650.001]

[Cites] Int J Cancer. 1999 Nov 12;83(4):564-70 [10508495.001]

[Cites] AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1389-98 [10515154.001]

[Cites] J Biol Chem. 2005 Mar 18;280(11):10491-500 [15637055.001]

[Cites] Oncogene. 2005 Mar 24;24(13):2121-43 [15789036.001]

[Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]

[Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]

[Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]

[Cites] J Biol Chem. 2006 Apr 14;281(15):10153-63 [16478725.001]

[Cites] Blood. 1992 Jul 15;80(2):498-504 [1320956.001]

[Cites] Blood. 1994 Feb 15;83(4):1067-78 [8111047.001]

[Cites] Oncogene. 1995 Oct 19;11(8):1615-22 [7478586.001]

[Cites] J Interferon Cytokine Res. 1995 Mar;15(3):261-8 [7584673.001]

[Cites] Cancer Res. 1996 Jan 1;56(1):40-3 [8548771.001]

[Cites] Virology. 1995 Dec 20;214(2):431-8 [8553544.001]

[Cites] Blood. 1996 Aug 1;88(3):809-16 [8704235.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]

[Cites] Immunity. 1996 Nov;5(5):449-60 [8934572.001]

[Cites] Blood. 1997 Feb 1;89(3):941-7 [9028325.001]

[Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5877-81 [9159168.001]

[Cites] AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1589-96 [9430251.001]

[Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]

[Cites] Br J Haematol. 1998 Oct;103(1):143-9 [9792301.001]

[Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]

[Cites] Br J Haematol. 1999 Nov;107(2):392-5 [10583232.001]

(PMID = 17324269.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA074731; United States / NCI NIH HHS / CA / R01 CA74731

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interleukin-6; 0 / Transforming Growth Factor beta1

[Other-IDs] NLM/ PMC1810304

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma.

BACKGROUND: Human immunodeficiency virus (HIV) infection is known to be associated with an increased risk of non-Hodgkin's lymphoma (NHL).

Treatment of NHL is not standardized.

OBJECTIVES: To assess the clinical effectiveness and safety of single agent or combination chemotherapy with or without immunochemotherapy (rituximab) and with or without highly active antiretroviral therapy (HAART) on overall survival (OS) and disease-free survival (DFS) for previously untreated patients with AIDS-related NHL.

For additional information see the Cochrane HIV/AIDS Group search strategy.

SELECTION CRITERIA: Randomized controlled trials (RCTs) assessing the effectiveness of systemic treatments for previously untreated AIDS-related NHL.

AUTHORS' CONCLUSIONS: We found no evidence that the systemic interventions for untreated patients with AIDS-related NHL provide superior clinical effectiveness for improving OS, DSF, and tumour response rate; however, this conclusion is based on four RCTs with limited sample size and variable quality.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

HIV InSite. treatment guidelines - Pneumocystosis and HIV .

Hazardous Substances Data Bank. BLEOMYCIN .

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINDESINE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. LEUCOVORIN .

Hazardous Substances Data Bank. METHOTREXATE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19588373.001).

[ISSN] 1469-493X

[Journal-full-title] The Cochrane database of systematic reviews

[ISO-abbreviation] Cochrane Database Syst Rev

[Language] eng

[Publication-type] Journal Article; Meta-Analysis; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q573I9DVLP / Leucovorin; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; LNH 87 protocol; M-BACOD protocol; VAP-cyclo protocol

[Number-of-references] 112

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] How valid is using cancer registries' data to identify acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma?

OBJECTIVE: We sought to determine the accuracy of cancer registry data regarding the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) status of patients with non-Hodgkin's lymphoma (NHL).

METHODS: We used the population-based San Diego/Orange County cancer registry to identify 392 patients with HIV-related NHL diagnosed 1994-1999.

After matching for age, sex, race, period of NHL diagnosis, and hospital type, we were able to find 324 corresponding patients among the remaining 4,863 NHL patients diagnosed 1994-1999 (who did not have HIV infection according to cancer registry records).

CONCLUSION: Using cancer registry data to identify AIDS-related NHL is a valid research practice.

[MeSH-major] Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Medical Records / standards. Population Surveillance / methods. Registries / standards. SEER Program / standards

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17235495.001).

[ISSN] 0957-5243

[Journal-full-title] Cancer causes & control : CCC

[ISO-abbreviation] Cancer Causes Control

[Language] eng

[Grant] United States / NCI NIH HHS / CA / K07 CA96480

[Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS.

We used the San Diego/Orange County cancer registry to identify 64 cases of systemic non-Hodgkin's lymphoma (NHL) with AIDS who received highly active antiretroviral therapy (HAART) at the time of NHL diagnosis or thereafter and 64 NHL controls without AIDS, matched on age, sex, race, time of NHL diagnosis (1994-1995 and 1996-1999), and hospital type (academic, large community, and small community).

Patients with AIDS-related NHL who received HAART had high grade histology and baseline cytopenia and received reduced-dose chemotherapy more often than patients without AIDS.

However, AIDS patients who received HAART and chemotherapy had survival similar to NHL patients without AIDS, an improvement from the pre-HAART era.

Appropriate hematologic support, through growth factors, transfusions, and avoidance of drugs with hematologic toxicity, might allow full dosing of chemotherapy, and perhaps would further improve outcomes among patients with AIDS and NHL.

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17064995.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Grant] United States / NCI NIH HHS / CA / 1K07 CA 096480

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma.

The late effects of chemotherapy on immunologic parameters in AIDS-related non-Hodgkin lymphoma (NHL) have not been described.

Chemotherapy and concomitant HAART for AIDS-related NHL does not cause prolonged suppression of lymphocyte subsets.

[MeSH-major] Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / immunology

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Blood. 2008 Apr 15;111(8):3921-2 [18434970.001]

(PMID = 18172004.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-HIV Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study.

BACKGROUND: Cytokine stimulation of B-cell proliferation may be an important causative mechanism for acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma (NHL).

The Epstein-Barr virus (EBV) may be a co-factor, particularly for primary central nervous system (CNS) tumors, which are uniformly EBV-positive in the setting of AIDS.

Thus, we examined associations of genetic variation in IL10 and related cytokine-signaling molecules (IL10RA, CXCL12, IL13, IL4, IL4R, CCL5 and BCL6) with AIDS-related NHL risk and evaluated differences between primary CNS and systemic tumors.

PATIENTS AND MATERIALS: We compared 160 Multicenter AIDS Cohort Study (MACS) participants with incident lymphomas, of which 90 followed another AIDS diagnosis, to HIV-1-seropositive controls matched on duration of lymphoma-free survival post-HIV-1 infection (N = 160) or post-AIDS diagnosis (N = 90).

RESULTS: Carriage of at least one copy of the T allele for the IL10 rs1800871 (as compared to no copies) was associated with decreased AIDS-NHL risk specific to lymphomas arising from the CNS (CC vs. CT/TT: OR = 0.3; 95% CI 0.1, 0.7) but not systemically (CC vs. CT/TT: OR = 1.0; 95% CI 0.5, 1.9) (Pheterogeneity = 0.03).

Carriage of two copies of the 'low IL10' haplotype rs1800896_A/rs1800871_T/rs1800872_A was associated with decreased lymphoma risk that varied by number of copies (Ptrend = 0.02).

CONCLUSION: Excessive IL10 response to HIV-1 infection may be associated with increased risk of NHL, particularly in the CNS.

IL10 dysregulation may be an important causative pathway for EBV-related lymphomagenesis.

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Infect Dis. 2000 Mar;181(3):872-80 [10720507.001]

[Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]

[Cites] J Clin Oncol. 2000 Oct 1;18(19):3325-30 [11013271.001]

[Cites] EMBO J. 2000 Dec 15;19(24):6742-50 [11118209.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14467-72 [11121048.001]

[Cites] Arthritis Rheum. 2001 Jan;44(1):176-9 [11212157.001]

[Cites] J Infect Dis. 2001 Sep 15;184(6):777-80 [11517440.001]

[Cites] Pharmacol Ther. 2002 Sep;95(3):295-304 [12243799.001]

[Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]

[Cites] Immunogenetics. 2003 Dec;55(9):629-32 [14605776.001]

[Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]

[Cites] Science. 1990 Jun 8;248(4960):1230-4 [2161559.001]

[Cites] Science. 1990 Nov 9;250(4982):830-2 [2173142.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]

[Cites] Blood. 1993 Jan 1;81(1):166-76 [8380252.001]

[Cites] Br J Haematol. 1995 Jun;90(2):235-43 [7794745.001]

[Cites] Clin Exp Allergy. 1995 Nov;25 Suppl 2:74-8; discussion 95-6 [8590350.001]

[Cites] J Natl Cancer Inst. 1996 May 15;88(10):675-9 [8627644.001]

[Cites] Acta Haematol. 1996;95(3-4):193-8 [8677742.001]

[Cites] Ann Intern Med. 1997 Jun 15;126(12):946-54 [9182471.001]

[Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]

[Cites] Br J Haematol. 1998 Oct;103(1):143-9 [9792301.001]

[Cites] J Immunol. 1999 Feb 1;162(3):1827-35 [9973448.001]

[Cites] Arthritis Rheum. 1999 Jun;42(6):1101-8 [10366102.001]

[Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]

[Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]

[Cites] Blood. 2006 Apr 1;107(7):2928-35 [16332968.001]

[Cites] JAMA. 2006 Sep 27;296(12):1498-506 [17003398.001]

[Cites] Genes Immun. 2006 Dec;7(8):615-24 [16971956.001]

[Cites] Carcinogenesis. 2007 Mar;28(3):704-12 [17056605.001]

[Cites] Leuk Lymphoma. 2007 Nov;48(11):2235-8 [17990180.001]

[ErratumIn] AIDS. 2010 Jul 31;24(12):1973

(PMID = 20299965.001).

[ISSN] 1473-5571

[Journal-full-title] AIDS (London, England)

[ISO-abbreviation] AIDS

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NCI NIH HHS / CA / R01 CA073475; United States / NIAID NIH HHS / AI / UO1-AI-37984; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CA / P50-CA-096888; United States / NCI NIH HHS / CA / R01-CA57152; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NCI NIH HHS / CA / R01 CA057152; United States / Intramural NIH HHS / / Z99 CA999999; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NCI NIH HHS / CA / P50 CA096888; United States / NIAID NIH HHS / AI / UO1-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NCI NIH HHS / CA / R01-CA73475

[Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

[Publication-country] England

[Chemical-registry-number] 0 / Cytokines; 130068-27-8 / Interleukin-10

[Other-IDs] NLM/ NIHMS192123; NLM/ PMC3950937

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] T-cell lymphoma of the rectum in a patient with AIDS and hepatitis C: a case report and discussion.

Primary T-cell non-Hodgkin's lymphoma (NHL) occurring in the context of acquired immune deficiency syndrome (AIDS) is uncommon.

Although typical in some respects, the case is, in other ways, somewhat unusual for an AIDS-related NHL (ARL); ARL tends to be B cell and advanced stage and our case was T cell and stage IE.

In addition, the patient suffered from concomitant cirrhosis related to hepatitis C.

Chemotherapeutic options for ARL were limited early in the AIDS epidemic due to poor tolerability.

Although this has largely been mitigated by the advent of highly active antiretroviral therapy, our patient eventually suffered complications of chemotherapy, apparently related more to his liver disease than to either his lymphoma or AIDS, that ultimately brought about his demise.

[MeSH-major] AIDS-Related Opportunistic Infections / complications. Hepatitis C / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, T-Cell / diagnosis. Rectal Neoplasms / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hepatitis.

MedlinePlus Health Information. consumer health - Hepatitis C.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15821249.001).

[ISSN] 1083-7159

[Journal-full-title] The oncologist

[ISO-abbreviation] Oncologist

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The major histocompatibility complex conserved extended haplotype 8.1 in AIDS-related non-Hodgkin lymphoma.

BACKGROUND: Two single nucleotide polymorphisms (SNPs) in adjacent genes, lymphotoxin alpha (LTA +252G, rs909253 A>G) and tumor necrosis factor (TNF -308A, rs1800629 G>A), form the G-A haplotype repeatedly associated with increased risk of non-Hodgkin lymphoma (NHL) in individuals uninfected with HIV-1.

OBJECTIVE: We aimed to determine whether the reported association of the G-A haplotype of LTA-TNF with non-AIDS NHL also occurs with AIDS-related NHL.

METHODS: SNPs in LTA and TNF and in 6 other genes nearby were typed in 140 non-Hispanic European American pairs of AIDS-NHL cases and matched controls selected from HIV-infected men in the Multicenter AIDS Cohort Study.

RESULTS: The G-A haplotype and a 4-SNP haplotype in the neighboring gene cluster (rs537160 (A) rs1270942 (G), rs2072633 (A), and rs6467 (C)) were associated with AIDS-NHL (odds ratio = 2.7, 95% confidence interval: 1.5 to 4.8, P = 0.0009; and odds ratio = 3.2, 95% confidence interval: 1.6 to 6.6, P = 0.0008; respectively).

CONCLUSION: The CEH 8.1-specific haplotype association of MHC class III variants with AIDS-NHL closely resembles that observed for non-AIDS NHL.

Corroboration of an MHC determinant of AIDS and non-AIDS NHL alike would imply an important pathogenetic mechanism common to both.

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Curr Opin Pharmacol. 2004 Aug;4(4):314-20 [15251122.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195-9 [9096369.001]

[Cites] Lancet. 1990 Apr 21;335(8695):927-30 [1970024.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] Hum Immunol. 1992 Aug;34(4):242-52 [1464552.001]

[Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]

[Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]

[Cites] Biometrics. 1999 Dec;55(4):997-1004 [11315092.001]

[Cites] Eur J Cancer. 2001 Jul;37(10):1316-9 [11423263.001]

[Cites] Hum Hered. 2002;53(2):79-91 [12037407.001]

[Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]

[Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]

[Cites] Blood. 2002 Oct 15;100(8):3037-40 [12351419.001]

[Cites] Genome Res. 2004 Jun;14(6):1176-87 [15140828.001]

[Cites] J Hered. 1995 Sep-Oct;86(5):409-11 [7560877.001]

[Cites] Mol Biol Evol. 1995 Sep;12(5):921-7 [7476138.001]

[Cites] Transplantation. 1995 Nov 27;60(10):1113-7 [7482718.001]

[Cites] J Neuroimmunol. 1995 Dec 31;63(2):143-7 [8550811.001]

[Cites] Clin Exp Immunol. 1996 Mar;103(3):391-6 [8608636.001]

[Cites] J Neuroimmunol. 1997 Feb;72(2):149-53 [9042107.001]

[Cites] Blood. 1998 May 15;91(10):3574-81 [9572991.001]

[Cites] Clin Exp Immunol. 1998 Sep;113(3):401-6 [9737669.001]

[Cites] Immunol Rev. 1999 Feb;167:257-74 [10319267.001]

[Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]

[Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]

[Cites] J Med Virol. 2005 Jul;76(3):302-10 [15902698.001]

[Cites] Nat Genet. 2005 Nov;37(11):1217-23 [16244653.001]

[Cites] J Clin Oncol. 2005 Nov 20;23(33):8414-21 [16293872.001]

[Cites] J Infect Dis. 2006 Jan 1;193(1):16-26 [16323127.001]

[Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]

[Cites] Eur J Cancer. 2006 Apr;42(6):745-50 [16517151.001]

[Cites] Br J Haematol. 2006 May;133(3):293-300 [16643431.001]

[Cites] Diabetes. 2006 May;55(5):1265-9 [16644681.001]

[Cites] Genomics. 2006 May;87(5):561-71 [16434165.001]

[Cites] Blood. 2006 May 15;107(10):4101-8 [16449530.001]

[Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W621-5 [16845085.001]

[Cites] Cancer Res. 2006 Oct 1;66(19):9771-80 [17018637.001]

[Cites] Genes Chromosomes Cancer. 2007 May;46(5):500-7 [17311253.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8 [17337643.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]

[Cites] Cancer Res. 2007 May 15;67(10):5042-54 [17510437.001]

[Cites] Tissue Antigens. 2008 Jan;71(1):16-26 [17971052.001]

[Cites] Immunogenetics. 2008 Jan;60(1):1-18 [18193213.001]

[Cites] Int J Immunogenet. 2008 Jun;35(3):179-92 [18397301.001]

[Cites] Carcinogenesis. 2007 Mar;28(3):704-12 [17056605.001]

[Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]

(PMID = 19654554.001).

[ISSN] 1944-7884

[Journal-full-title] Journal of acquired immune deficiency syndromes (1999)

[ISO-abbreviation] J. Acquir. Immune Defic. Syndr.

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NCI NIH HHS / CA / R01 CA073475-03; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NCI NIH HHS / CA / R01 CA073475; United States / NIAID NIH HHS / AI / UO1-AI-37984; United States / NCI NIH HHS / CA / R01 CA106168-01A1; United States / NCI NIH HHS / CA / CA106168-01A1; United States / NCI NIH HHS / CA / P50-CA96888; United States / NCI NIH HHS / CA / R01 CA106168; United States / NCI NIH HHS / CA / CA073475-03; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NCI NIH HHS / CA / P50 CA096888-01; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NIAID NIH HHS / AI / P30 AI045008; United States / NIAID NIH HHS / AI / UO1-AI-35040,; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / P30 AI045008-01; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NCI NIH HHS / CA / R01-CA106168; United States / NIAID NIH HHS / AI / AI045008-01; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NCI NIH HHS / CA / CA096888-01; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NCI NIH HHS / CA / P50 CA096888; United States / NIAID NIH HHS / AI / P30 AI 045008; United States / NIAID NIH HHS / AI / UO1-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NCI NIH HHS / CA / R01-CA73475

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / HLA Antigens; 0 / Lymphotoxin-alpha; 0 / Tumor Necrosis Factor-alpha

[Other-IDs] NLM/ NIHMS250460; NLM/ PMC3015185

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma.

We previously observed a loss of Epstein-Barr virus (EBV)-specific CD8+ T cells in subjects progressing to EBV-related non-Hodgkin lymphoma (NHL), correlating with loss of CD4+ T cells.

The aim of the present study was to determine the role of EBV-specific CD4+ T cells in the development of NHL during chronic HIV infection.

To this end, CD4+ and CD8+ memory T cells, capable of both proliferation and subsequent interferon gamma (IFNgamma) production, directed against a latent (Epstein-Barr virus nuclear antigen 1 [EBNA1]) and a lytic (BamH fragment Z left frame 1 [BZLF1]) EBV antigen were studied longitudinally in 9 progressors to NHL, 4 progressors to non-EBV-related AIDS, and 4 slow progressors to AIDS.

However, whereas latent antigen EBNA1-specific CD4+ T cells were lost well before diagnosis in all subjects who developed an AIDS-related NHL (and EBNA1-specific CD8+ T cells were significantly lower compared with the other groups), these cells were better preserved in progressors to non-EBV-related disease and slow progressors.

Loss of EBNA1-specific T-cell immunity thus might be important for progression to NHL.

Interestingly, BZLF1-specific T cells were not lost in all progressors to NHL, suggesting a different function of these cells in the surveillance of EBV-infected B cells.

[MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Epstein-Barr Virus Nuclear Antigens / immunology. Immunologic Memory / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / immunology

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16014568.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Non-Hodgkin's lymphoma in the elderly.

The expansion of older population segments and the continuous increase in the incidence of non-Hodgkin's lymphoma (NHL) makes this group of neoplasms an important and growing problem.

Older NHL patients have increased risk of therapy-related toxicity as a result of age-related physiological changes and frequent co-morbidities.

The comprehensive geriatric assessment (CGA) is one multidisciplinary tool that has been applied successfully to older cancer patients and aids in identification of subjects who will or will not benefit from anti-neoplastic treatment.

Diffuse large B-cell lymphoma is an aggressive but potentially curable disease.

Highly selected individuals up to age 70 years may attain long-term survival benefit from autoHCT, although transplant-related mortality is higher than in younger patients.

[MeSH-major] Aging / physiology. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / physiopathology. Lymphoma, Non-Hodgkin / therapy

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Seniors' Health.

Hazardous Substances Data Bank. RITUXIMAB .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20210368.001).

[ISSN] 1179-1969

[Journal-full-title] Drugs & aging

[ISO-abbreviation] Drugs Aging

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] New Zealand

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related non-Hodgkin's lymphomas.

This work reviews the current status of non-Hodgkin's lymphoma (NHL) in HIV infected patients.

HIV infection remains at significantly increased risk for the development of NHL.

A number of genetic abnormalities have been found but additional studies are necessary to understand the etiology and pathogenesis of NHL in the setting of HIV infection.

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, AIDS-Related / pathology. Lymphoma, Non-Hodgkin / etiology

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2005 Wiley-Liss, Inc.

(PMID = 16276515.001).

[ISSN] 1059-910X

[Journal-full-title] Microscopy research and technique

[ISO-abbreviation] Microsc. Res. Tech.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 50

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients].

BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.

One of the major clinical characteristics of AIDS-associated NHL is the high frequency of extra-nodal involvement, including the gastrointestinal tract, at initial presentation.

METHODS: From January 1997 to December 2004, 8 cases of NHL of the digestive tract and anexal glands (liver and parotid gland) were observed at the HIV/AIDS division of the Infectious Diseases FJ Muñiz Hospital from Buenos Aires, Argentina.

No patient was receiving highly active antiretroviral therapy (HAART) at lymphoma diagnosis.

The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.

Primary duodenal lymphoma was the only Burkitt lymphoma of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic lymphoma.

CONCLUSION: NHL of the gastrointestinal tract is a severe complication of advanced HIV/AIDS disease.

[MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Liver Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17225446.001).

[ISSN] 0300-9033

[Journal-full-title] Acta gastroenterologica Latinoamericana

[ISO-abbreviation] Acta Gastroenterol. Latinoam.

[Language] spa

[Publication-type] English Abstract; Journal Article

[Publication-country] Argentina

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma.

Despite HAART, patients infected with HIV develop NHL at a significantly higher level than the noninfected population.

The primary difference between lymphoma in non-HIV-infected individuals and those with ARL is that ARL is consistently high-grade and metastatic.

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] HIV Clin Trials. 2003 Mar-Apr;4(2):137-43 [12671782.001]

[Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]

[Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]

[Cites] Blood. 2004 Oct 15;104(8):2224-34 [15231578.001]

[Cites] J Neurosurg. 1979 Mar;50(3):305-11 [422981.001]

[Cites] Science. 1983 Apr 8;220(4593):210-2 [6828888.001]

[Cites] Science. 1984 Sep 7;225(4666):1034-6 [6089338.001]

[Cites] Lancet. 1987 Apr 25;1(8539):952-4 [2882343.001]

[Cites] Br J Cancer. 1987 Jul;56(1):15-9 [3304388.001]

[Cites] J Neurosurg. 1990 Aug;73(2):206-11 [2366078.001]

[Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

[Cites] Cancer Res. 2005 Jun 15;65(12):5278-83 [15958574.001]

[Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]

[Cites] Curr HIV Res. 2005 Oct;3(4):303-17 [16250878.001]

[Cites] Blood. 2006 Jan 1;107(1):277-84 [16150942.001]

[Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]

[Cites] J Virol. 2006 Mar;80(5):2472-82 [16474154.001]

[Cites] Curr Opin Oncol. 2006 Sep;18(5):444-8 [16894291.001]

[Cites] Mol Immunol. 2007 Feb;44(5):934-42 [16730063.001]

[Cites] J Clin Oncol. 2006 Nov 1;24(31):5052-9 [17033038.001]

[Cites] Haematologica. 2006 Dec;91(12):1605-12 [17145596.001]

[Cites] Yale J Biol Med. 2006 Dec;79(3-4):123-30 [17940622.001]

[Cites] APMIS. 2007 Oct;115(10):1135-46 [18042147.001]

[Cites] J Virol. 1991 Jan;65(1):356-63 [1985204.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] Melanoma Res. 1992 Jul;2(2):127-9 [1643432.001]

[Cites] Curr Opin Oncol. 1992 Oct;4(5):900-6 [1457505.001]

[Cites] Blood. 1993 Apr 15;81(8):2102-9 [8386027.001]

[Cites] Lancet. 1993 Jul 17;342(8864):148-9 [8101258.001]

[Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]

[Cites] Nat Med. 1996 Dec;2(12):1371-5 [8946838.001]

[Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]

[Cites] J Immunother. 1997 May;20(3):165-77 [9181454.001]

[Cites] Am J Pathol. 1998 Mar;152(3):623-30 [9502401.001]

[Cites] EMBO J. 1998 Mar 16;17(6):1700-9 [9501091.001]

[Cites] J Clin Invest. 1998 Apr 15;101(8):1693-8 [9541500.001]

[Cites] J Leukoc Biol. 1998 Sep;64(3):275-90 [9738653.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8212-6 [10393974.001]

[Cites] Nat Med. 1999 Sep;5(9):997-103 [10470075.001]

[Cites] AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1389-98 [10515154.001]

[Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]

[Cites] Br J Cancer. 1999 Feb;79(5-6):965-70 [10070898.001]

[Cites] Leuk Lymphoma. 2007 Dec;48(12):2403-11 [18067016.001]

[Cites] AIDS. 2007 Nov 12;21(17):2265-70 [18090274.001]

[Cites] J Infect Dis. 2008 Jan 15;197(2):309-18 [18173363.001]

[Cites] Int J Cancer. 2008 Jul 1;123(1):73-84 [18398829.001]

[Cites] Pathol Int. 2008 Aug;58(8):529-32 [18705775.001]

[Cites] Curr HIV Res. 2008 Sep;6(5):388-400 [18855649.001]

[Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]

[Cites] Curr Opin Oncol. 2008 Sep;20(5):534-40 [19106656.001]

[Cites] PLoS One. 2009;4(3):e5065 [19333384.001]

[Cites] J Clin Oncol. 2009 Oct 20;27(30):5039-48 [19752343.001]

[Cites] Int J Cancer. 2010 Jan 1;126(1):65-72 [19536778.001]

[Cites] PLoS One. 2009;4(12):e8153 [19997510.001]

[Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]

[Cites] J Acquir Immune Defic Syndr. 2000 Feb 1;23(2):114-9 [10737425.001]

[Cites] J Clin Invest. 2000 Jul;106(1):11-3 [10880043.001]

[Cites] AIDS. 2000 Jul 28;14(11):1583-9 [10983645.001]

[Cites] Melanoma Res. 2000 Dec;10(6):507-14 [11198471.001]

[Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]

[Cites] Nature. 2001 Apr 19;410(6831):988-94 [11309629.001]

[Cites] Eur J Cancer. 2001 Jul;37(10):1236-50 [11423256.001]

[Cites] Eur J Cancer. 2001 Jul;37(10):1316-9 [11423263.001]

[Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]

[Cites] J Virol. 2002 Jan;76(2):707-16 [11752161.001]

[Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]

[Cites] Annu Rev Neurosci. 2002;25:537-62 [12052920.001]

[Cites] Hum Pathol. 2002 Apr;33(4):392-404 [12055673.001]

[Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]

[Cites] Curr Opin Oncol. 2002 Sep;14(5):528-32 [12192272.001]

[Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]

[Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]

[Cites] Cell. 2003 Mar 7;112(5):645-57 [12628185.001]

(PMID = 20042471.001).

[ISSN] 1938-3673

[Journal-full-title] Journal of leukocyte biology

[ISO-abbreviation] J. Leukoc. Biol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / 5 U01 CA 066529-14; United States / NCI NIH HHS / CA / 5 U01 CA096230-06

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Chemotactic Factors; 0 / HIV Core Protein p24

[Number-of-references] 75

[Other-IDs] NLM/ PMC2858304

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.

BACKGROUND: Non-Hodgkin lymphoma (NHL) associated with HIV became an AIDS-defining condition early in the epidemic and remains the second most common malignancy in patients with AIDS.

With the advent of highly active antiretroviral therapy (HAART), the incidence and mortality of AIDS-related opportunistic infections and Kaposi's sarcoma has fallen dramatically, this trend is not observed so clearly for NHL.

Our objective was to review the clinical spectrum of patients with AIDS-associated NHL and to analyze the impact of HAART on survival at an oncological tertiary center.

MATERIAL AND METHODS: We reviewed all medical records and histopathologic tissue of patients with HIV-associated NHL seen from January 1990 to September 2007 at the Instituto Nacional de Cancerologia in Mexico City.

RESULTS: Eighty seven HIV-positive patients were diagnosed with NHL (diffuse large B-cell lymphoma n=69; Burkitt-like n=8; pleomorphic large cell n=7; low-grade n=2, and angiocentric n=1).

Overall, 38 patients (43.7%) achieved complete response to NHL therapy, including only 14.3% patients in the non-HAART compared with 57.6% in the HAART group (p < or = 0.0001).

Two patients (7.1%) in the non-HAART were alive compared with 37 (63.8%) in the HAART group (p < or = 0.0001).

CONCLUSIONS: Patients with NHL-HIV who were able to receive treatment with HAART and were sufficiently healthy to receive optimal chemotherapy treatment showed a significantly better prognosis.

[MeSH-major] Cancer Care Facilities / statistics & numerical data. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Non-Hodgkin / epidemiology

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19227434.001).

[ISSN] 0034-8376

[Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición

[ISO-abbreviation] Rev. Invest. Clin.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Mexico

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood.

PURPOSE: To determine the relative frequency with which Kaposi's sarcoma-associated herpesvirus/HHV-8 (KSHV) DNA is detected in peripheral-blood mononuclear cells (PBMCs) and in plasma of patients with AIDS-KS and AIDS-associated non-Hodgkin's lymphoma (NHL; AIDS-NHL); to determine whether the presence of viral DNA in plasma reflects lysis of tumor cells or reflects the presence of viremia (ie, virion-encapsidated DNA); and to determine the effect of lymphoma therapy on KSHV DNA.

PATIENTS AND METHODS: Samples were obtained from patients enrolled in AIDS Malignancy Consortium clinical trials and from healthy donors.

RESULTS: In patients with AIDS-KS, KSHV DNA was detected in PBMC (54%) and in plasma (62%).

In patients with AIDS-NHL, KSHV DNA was detected in PBMC (19%) and in plasma (22%).

In six patients with AIDS-NHL who were treated with chemotherapy (with or without rituximab), KSHV copy number declined in PBMC and in plasma.

CONCLUSION: KSHV DNA is sometimes detected in PBMC or in plasma of patients with AIDS-NHL without KS.

Among patients with KSHV DNA detected in PBMC or in plasma, copy number does not distinguish between patients with AIDS-NHL and AIDS-KS.

KSHV DNA copy number in PBMC and in plasma declined with lymphoma-directed cytotoxic chemotherapy in each of the six patients studied.

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]

[Cites] AIDS. 2007 Jul 31;21(12):1541-5 [17630548.001]

[Cites] Blood. 2000 Dec 15;96(13):4055-63 [11110673.001]

[Cites] Cancer Res. 2001 Feb 15;61(4):1659-65 [11245480.001]

[Cites] J Clin Oncol. 2002 Jan 1;20(1):153-9 [11773164.001]

[Cites] J Virol. 2002 Apr;76(7):3421-39 [11884567.001]

[Cites] Clin Chem. 2002 Aug;48(8):1186-93 [12142371.001]

[Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9 [12419787.001]

[Cites] J Infect Dis. 2003 Jan 1;187(1):149-53 [12508160.001]

[Cites] Clin Infect Dis. 2003 May 1;36(9):1144-51 [12715309.001]

[Cites] J Clin Oncol. 2007 Aug 1;25(22):3350-6 [17664482.001]

[Cites] J Infect Dis. 2007 Oct 15;196(8):1163-6 [17955434.001]

[Cites] Blood. 2007 Dec 1;110(12):4132-3 [18024800.001]

[Cites] Ann Intern Med. 2007 Dec 18;147(12):836-9 [18087054.001]

[Cites] Blood. 2008 Apr 15;111(8):3986-90 [18172004.001]

[Cites] Cancer Lett. 2008 May 18;263(2):182-8 [18234418.001]

[Cites] J Infect Dis. 2008 Jul 1;198(1):23-30 [18491970.001]

[Cites] Cancer Res. 2003 May 1;63(9):2028-32 [12727814.001]

[Cites] AIDS. 2004 Feb 20;18(3):485-93 [15090801.001]

[Cites] Diagn Mol Pathol. 2004 Jun;13(2):61-8 [15167006.001]

[Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6189-93 [15448006.001]

[Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]

[Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]

[Cites] Am J Pathol. 1996 Jun;148(6):1741-8 [8669460.001]

[Cites] Blood. 1996 Jul 1;88(1):297-301 [8704186.001]

[Cites] J Infect Dis. 1996 Nov;174(5):1101-5 [8896516.001]

[Cites] AIDS. 1997 Apr;11(5):F35-45 [9108935.001]

[Cites] J Virol. 1997 Oct;71(10):7963-8 [9311888.001]

[Cites] J Infect Dis. 1999 Sep;180(3):824-8 [10438372.001]

[Cites] J Infect Dis. 2005 Feb 1;191(3):367-71 [15633095.001]

[Cites] J Clin Oncol. 2005 Feb 10;23(5):990-8 [15598977.001]

[Cites] J Am Acad Dermatol. 2005 Jul;53(1):155-7 [15965441.001]

[Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]

[Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):149-53 [16394845.001]

[Cites] Ann Hematol. 2006 Mar;85(3):185-7 [16341862.001]

[Cites] Int J Cancer. 2006 Dec 1;119(11):2673-6 [16991120.001]

[Cites] J Clin Oncol. 2006 Dec 1;24(34):5414-8 [17135642.001]

[Cites] N Engl J Med. 2000 Nov 9;343(19):1411-3 [11070109.001]

(PMID = 19349542.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / P50 CA96888; United States / NCI NIH HHS / CA / U01 CA070047; United States / NCI NIH HHS / CA / U01 CA070019; United States / NCI NIH HHS / CA / U01 CA083038; United States / NCI NIH HHS / CA / U01 CA083035; United States / NCI NIH HHS / CA / U01 CA070072; United States / NCI NIH HHS / CA / U01 CA083118; United States / NCI NIH HHS / CA / U01 CA070081; United States / NCI NIH HHS / CA / U01 CA071375; United States / NCI NIH HHS / CA / U01 CA070079; United States / NCI NIH HHS / CA / U01 CA070054; United States / NCI NIH HHS / CA / U01 CA70081; United States / NCI NIH HHS / CA / U01 CA070062; United States / NCI NIH HHS / CA / U01 CA70058; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / U01 CA070080; United States / NCI NIH HHS / CA / P50 CA096888

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral

[Other-IDs] NLM/ PMC2684854

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin's lymphoma.

We sought to determine how the use of HAART influenced survival among patients with acquired immunodeficiency syndrome (AIDS) and primary central nervous system (CNS) non-Hodgkin's lymphoma (NHL).

We used the population-based San Diego and Orange County cancer registry to identify 94 patients with both AIDS and CNS NHL diagnosed 1994-1999, of whom 31 were diagnosed 1996-1999.

We performed Kaplan-Meier analyses to compare survival between patients who received HAART at NHL diagnosis or thereafter versus untreated patients and Cox proportional hazard models for adjusted survival.

Among the patients diagnosed with NHL in 1996-1999, seven (23%) were taking HAART at the time of NHL diagnosis.

Median survival was eight months for those who received HAART at the time of lymphoma diagnosis or after, versus one month for untreated patients.

We conclude that HAART prolongs survival in AIDS-related CNS NHL.

[MeSH-major] Antiretroviral Therapy, Highly Active. Central Nervous System Neoplasms / mortality. Lymphoma, AIDS-Related / mortality

Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16842088.001).

[ISSN] 1570-162X

[Journal-full-title] Current HIV research

[ISO-abbreviation] Curr. HIV Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / K07CA096480

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma.

CD30, first described as the Ki antigen on malignant B cells in Hodgkin's lymphoma, is also expressed on normal activated B and T cells.

In a cross-sectional study utilizing archived sera at a time point close to but preceding a diagnosis of acquired immunodeficiency syndrome (AIDS)-associated non-Hodgkin's B cell lymphoma, AIDS lymphoma subjects (n = 49) showed elevated mean levels of sCD30 compared to controls with AIDS but no malignancy (n = 44, p < 0.01), HIV-infected but relatively healthy (n = 47, p < 0.001), or HIV-seronegative controls (n = 44, p < 0.001).

Serum sCD30 was significantly correlated to serum levels of the B cell cytokines interleukin-6 (IL-6), IL-10, and sCD23, but only among lymphoma subjects (p < or = 0.05).

These observations suggest that sCD30, especially in combination with other immune system molecules, could be an important biomarker for an immune system environment conducive to B cell hyperactivation and the development of AIDS-associated B cell lymphoma.

[MeSH-major] Antigens, CD30 / blood. Lymphoma, AIDS-Related / immunology. Lymphoma, B-Cell / immunology

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2006 S. Karger AG, Basel.

(PMID = 16651853.001).

[ISSN] 1010-4283

[Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

[ISO-abbreviation] Tumour Biol.

[Language] eng

[Grant] United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / AI28697; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888; United States / NIAID NIH HHS / AI / U01-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NIAID NIH HHS / AI / UO1-AI-37984

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30; 0 / Biomarkers; 0 / Interleukins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hematopoietic cell transplantation in non-Hodgkin's lymphoma.

OBJECTIVE: To explore the role and outcomes using hematopoietic cell transplantation (HCT) as a treatment option with aggressive, follicular, mantle, T-cell, and HIV related non-Hodgkin's lymphoma (NHL).

CONCLUSION: High-dose chemotherapy and/or radiation therapy followed by HCT has been used to overcome resistance to standard-dose therapy and has been explored over the past 40 years and has shown long-term survival of approximately 10% to 50% in patients with relapsed or refractory lymphoma.

[MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy

[MeSH-minor] Humans. Lymphoma, AIDS-Related / nursing. Lymphoma, AIDS-Related / therapy. Lymphoma, Follicular / nursing. Lymphoma, Follicular / therapy. Lymphoma, Mantle-Cell / nursing. Lymphoma, Mantle-Cell / therapy. Lymphoma, T-Cell / nursing. Lymphoma, T-Cell / therapy. Transplantation Conditioning / adverse effects. Transplantation Conditioning / nursing

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16720233.001).

[ISSN] 0749-2081

[Journal-full-title] Seminars in oncology nursing

[ISO-abbreviation] Semin Oncol Nurs

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 46

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gingival primary extranodal non-Hodgkin's lymphoma as the first manifestation of acquired immunodeficiency syndrome.

BACKGROUND: Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative malignancies that may be associated with acquired immunodeficiency syndrome (AIDS).

NHL can disseminate to extranodal sites; however, its dissemination to the jaws and mouth is not common.

This report presents and discusses two unusual cases of gingival primary extranodal non-Hodgkin's lymphoma (PE-NHL) as the first manifestation of AIDS.

RESULTS: The clinicopathological evaluation and the serological HIV examination of the patients led us to the final diagnosis of gingival PE-NHL as the first manifestation of AIDS.

CONCLUSION: The present case reports have important clinical implications; the two unusual presentations of gingival PE-NHL contribute to information about the differential diagnosis of rapidly progressing gingival swelling.

[MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Gingival Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18315441.001).

[ISSN] 0022-3492

[Journal-full-title] Journal of periodontology

[ISO-abbreviation] J. Periodontol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Non Hodgkin's lymphoma with cutaneous involvement in AIDS patients: report of five cases and review of the literature.

Cutaneous B cell lymphoma (CBCL) is a lymphoproliferative disorder of neoplastic B cell of the skin with a wide range of clinical manifestations.

Skin is one of the common sites for extra-nodal lymphomas in patients with AIDS and B cell type is less common than T cell type.

Here, we are presenting 5 patients with cutaneous involvement in the setting of HIV/AIDS disease.

Two of them were primary cutaneous non-Hodgkin lymphomas.

All were CBCL; 3 were immunoblastic, 1 was plasmablastic, and the other was a Burkitt lymphoma.

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Skin Neoplasms / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20428660.001).

[ISSN] 1678-4391

[Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

[ISO-abbreviation] Braz J Infect Dis

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Brazil

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related malignancies: revisited.

Since the first reports between the association of Human Immunodeficiency Virus (HIV) infection and neoplasia, there has been a dramatic change in the incidence and epidemiology of AIDS-related malignancies.

Kaposi sarcoma (KS), non-Hodgkin's lymphomas (NHL), and cervical cancer are classified by the Centers for Disease Control and Prevention (CDC) as AIDS-defining malignancies.

However, since the availability of highly active combination antiretroviral therapy (cART), especially protease inhibitors, there has been a steady increase in non- AIDS defining malignancies, such as Hodgkin's lymphoma (HL), lung cancer, hepatocellular cancer, anal cancer and others and a decline in AIDS-defining neoplasias.

Although the emergence of non-AIDS defining cancers could be a result of longer life expectancy and due to a better control of HIV, toxic habits and co-infection with other viruses such as hepatitis B, hepatitis C and human papilloma virus (HPV) could play an important role.

The interactions of cART and incomplete immune reconstitution could be other factors explaining the increase in non-AIDS defining cancers.

These emerging non-AIDS defining malignancies present a new challenge in the care of patients with HIV infection, and require optimal treatment protocols that take into consideration the interaction between cART and systemic chemotherapy.

We review the current status of AIDS-related malignancies, its pathophysiology, epidemiology and management with emphasis in the changing patterns of presentation.

[MeSH-minor] Humans. Lymphoma, AIDS-Related / epidemiology

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20222338.001).

[ISSN] 0738-0658

[Journal-full-title] Puerto Rico health sciences journal

[ISO-abbreviation] P R Health Sci J

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Puerto Rico

[Number-of-references] 51

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.

Anthracyclines, including doxorubicin, are widely used in the treatment of B-cell non-Hodgkin's lymphoma (NHL).

Nonpegylated liposomal doxorubicin produced a promising response rate when substituted for conventional doxorubicin in the cyclophosphamide, doxorubicin, vincristine and prednisolone regimen in the treatment of patients with NHL either at diagnosis or at relapse.

The ability of nonpegylated liposomal doxorubicin to overcome excessive drug efflux due to P-glycoprotein (MDR-1) overexpression in NHL might confer on this drug a curative potential for patients with a bad prognosis (e.g., MDR-1 overexpressing, the elderly or frail).

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Lymphoma, B-Cell / drug therapy

[MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Humans. Liposomes. Lymphoma, AIDS-Related / drug therapy. Middle Aged. Prednisolone / administration & dosage. Vincristine / administration & dosage. Vincristine / therapeutic use

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19275512.001).

[ISSN] 1744-8328

[Journal-full-title] Expert review of anticancer therapy

[ISO-abbreviation] Expert Rev Anticancer Ther

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / Liposomes; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone

[Number-of-references] 31

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.

PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype.

PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.

RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001).

Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).

CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk.

Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.

Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]

[Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]

[Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]

[Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]

[Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]

[Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]

[Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]

[Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]

[Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]

[Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]

[Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]

[Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]

[Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]

[Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]

[Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]

[Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]

[Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]

[Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]

[Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]

[Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]

[Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]

[Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]

[Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]

[Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]

[Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]

[Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]

[Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]

[Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]

[Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]

[Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]

[Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]

[Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]

[Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]

[Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]

[Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]

[Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]

[Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]

[Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]

[Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]

[Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]

[Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]

[Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]

[Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]

[Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]

[Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]

[Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]

[Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]

[Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]

[Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]

[Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]

[Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]

(PMID = 20940199.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] ENG

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

[Other-IDs] NLM/ PMC3020697

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.

Central nervous system (CNS) lymphoma should always be considered because it is an important cause of morbidity and mortality.

RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS lymphoma.

This advantage suggests that, in case of negative flow cytometry results, disorders other than non-Hodgkin's lymphoma should be strongly considered.

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis

[MeSH-minor] Adult. Burkitt Lymphoma / cerebrospinal fluid. Burkitt Lymphoma / diagnosis. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15670248.001).

[ISSN] 1464-2662

[Journal-full-title] HIV medicine

[ISO-abbreviation] HIV Med.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.

Non-Hodgkin's lymphoma (NHL) remains an important complication of associated HIV infection despite advances in antiretroviral therapy (ART), and the optimum chemotherapy regimen for this disease remains to be defined.

Patients with aggressive histology HIV-related NHL who were previously untreated with chemotherapy, and who had no active opportunistic infection were eligible for the study.

Forty-seven patients were enrolled, most with diffuse large-cell or immunoblastic NHL.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

Genetic Alliance. consumer health - HIV.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. BLEOMYCIN .

Hazardous Substances Data Bank. Filgrastim .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16216784.001).

[ISSN] 1387-2656

[Journal-full-title] Biotechnology annual review

[ISO-abbreviation] Biotechnol Annu Rev

[Language] eng

[Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; VB0R961HZT / Prednisone; VACOP-B protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Attenuation of the epidemic increase in non-Hodgkin's lymphomas in Spain.

BACKGROUND: Attenuation of the epidemic increase in non-Hodgkin's lymphoma (NHL) incidence has recently been reported in the USA and Nordic European countries.

After two decades of steadily increasing NHL, this study sought to ascertain whether a similar stabilisation might have taken place in Spain in recent years.

PATIENTS AND METHODS: NHL cases were drawn from 13 population-based Spanish cancer registries with a record of at least 10 years of uninterrupted registration during the period 1975-2004.

RESULTS: A total of 21 335 NHL cases (11 531 male and 9804 female) were identified.

CONCLUSIONS: In Spain, NHL incidence levelled off in 1996 after a sharp increase during the 1970s and 1980s.

This stabilisation is, partially at least, linked to the decrease in incidence of AIDS-related lymphomas among young adults.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20427366.001).

[ISSN] 1569-8041

[Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology

[ISO-abbreviation] Ann. Oncol.

[Language] ENG

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Investigator] Dorronsorro M; Giraldo P; Díaz García JM; Gutiérrez G; Gutiérrez L; Pérez de Rada E

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.

Since the introduction of highly active antiretroviral therapy, there has been a decline in the incidence of non-Hodgkin's lymphoma among HIV-infected individuals.

We described trends in the incidence of systemic non-Hodgkin's lymphoma in the UK CHIC Study from 1996-2006 and evaluated the association between immunosuppression and development of systemic non-Hodgkin's lymphoma: 286/23,155 (1.2%) individuals developed an AIDS-defining lymphoma (258 systemic).

Younger age, receipt of highly active antiretroviral therapy and later calendar year were all independently associated with a reduced risk of systemic non-Hodgkin's lymphoma.

A lower latest CD4 count was strongly associated with systemic non-Hodgkin's lymphoma, in patients who had (RR per log(2)(cells/mm(3)) higher: 0.62) and had not (0.70) received highly active antiretroviral therapy.

Earlier highly active anti-retroviral therapy initiation and wider access to HIV testing is advocated to reduce the risk of systemic non-Hodgkin's lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Adv Exp Med Biol. 2001;495:205-12 [11774568.001]

[Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]

[Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]

[Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]

[Cites] J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):84-90 [14501799.001]

[Cites] Clin Infect Dis. 2003 Nov 1;37(9):1244-9 [14557970.001]

[Cites] HIV Med. 2004 Mar;5(2):115-24 [15012652.001]

[Cites] AIDS. 2004 Mar 5;18(4):673-81 [15090773.001]

[Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]

[Cites] BMJ. 1999 Jul 3;319(7201):23-4 [10390454.001]

[Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]

[Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]

[Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]

[Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]

[Cites] JAMA. 2006 Aug 16;296(7):827-43 [16905788.001]

[Cites] HIV Med. 2006 Nov;7(8):487-503 [17105508.001]

[Cites] PLoS Med. 2007 Mar 27;4(3):e96 [17388662.001]

[Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]

[Cites] HIV Med. 2008 Jul;9 Suppl 2:34-40 [18557871.001]

[Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]

[Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]

[Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]

[Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]

[Cites] Int J Cancer. 2003 Jan 1;103(1):142-4 [12455069.001]

(PMID = 19336735.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] ENG

[Grant] United Kingdom / Department of Health / / G0600337; United Kingdom / Medical Research Council / / G0000199; United Kingdom / Medical Research Council / / MC/ U122886351; United Kingdom / Medical Research Council / / G0200585; United Kingdom / Medical Research Council / / G0600337

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Other-IDs] NLM/ PMC2688582

[Investigator] Bower M; Fisher M; Hill T; Reeves I; Walsh J; Orkin C; Phillips AN; Bansi L; Gilson R; Easterbrook P; Johnson M; Gazzard B; Leen C; Pillay D; Schwenk A; Anderson J; Porter K; Gompels M; Sabin CA

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] An uncommon presentation of HIV-related lymphoma.

Although highly active antiretroviral therapy has improved the clinical course of patients with HIV, this population remains at a significantly increased risk for non-Hodgkin's lymphoma (NHL).

Spinal cord compression is a rare presentation of NHL, regardless of the patient population.

We encountered a patient with HIV-related NHL who presented with a thoracic spinal cord compression and had a complicated clinical course as a result of the atypical presentation.

[MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / complications. Lymphoma, Non-Hodgkin / virology. Spinal Cord Compression / etiology

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17651024.001).

[ISSN] 1087-2914

[Journal-full-title] AIDS patient care and STDs

[ISO-abbreviation] AIDS Patient Care STDS

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States